TW200716750A - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number: TW200716750A
Authority: TW; Taiwan
Prior art keywords: adenoviruses; vectors; hiv; relates; virus
Prior art date: 2005-05-12

Application number

TW095116578A

Other languages

English (en)

Inventor

Peter Franz Ertl

John Philip Tite

Wely Catherine Ann Van

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2006-05-10

Publication date

2007-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200716750(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-10 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-05-01 Publication of TW200716750A publication Critical patent/TW200716750A/zh

Links

229960005486 vaccine Drugs 0.000 title 1
239000013598 vector Substances 0.000 abstract 6
241000700605 Viruses Species 0.000 abstract 4
241000701161 unidentified adenovirus Species 0.000 abstract 4
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
241001217856 Chimpanzee adenovirus Species 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
241000990167 unclassified Simian adenoviruses Species 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Zoology (AREA)
AIDS & HIV (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TW095116578A 2005-05-12 2006-05-10 Vaccine composition TW200716750A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US68038905P	2005-05-12	2005-05-12

Publications (1)

Publication Number	Publication Date
TW200716750A true TW200716750A (en)	2007-05-01

Family

ID=36954770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095116578A TW200716750A (en)	2005-05-12	2006-05-10	Vaccine composition

Country Status (20)

Country	Link
US (1)	US20090208515A1 (zh)
EP (1)	EP1880012B1 (zh)
JP (2)	JP5175178B2 (zh)
KR (1)	KR101451620B1 (zh)
CN (2)	CN103088060A (zh)
AR (1)	AR053275A1 (zh)
AU (1)	AU2006245920A1 (zh)
BR (1)	BRPI0608798A2 (zh)
CA (1)	CA2608316A1 (zh)
EA (1)	EA200702190A1 (zh)
ES (1)	ES2546330T3 (zh)
IL (1)	IL186828A (zh)
MA (1)	MA29458B1 (zh)
MX (1)	MX2007014038A (zh)
NO (1)	NO20075648L (zh)
PE (1)	PE20061372A1 (zh)
SG (1)	SG182173A1 (zh)
TW (1)	TW200716750A (zh)
WO (1)	WO2006120034A1 (zh)
ZA (1)	ZA200709518B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU230488B1 (hu)	2001-11-21	2016-08-29	The Trustees Of The University Of Pennsylvania	Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20090246220A1 (en)	2006-08-28	2009-10-01	Ertl Hildegund C J	Constructs for enhancing immune responses
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN101675068A (zh) *	2007-03-02	2010-03-17	葛兰素史密丝克莱恩生物有限公司	新的方法和组合物
ES2607029T3 (es)	2007-11-28	2017-03-28	The Trustees Of The University Of Pennsylvania	Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
ES2621165T3 (es) *	2007-11-28	2017-07-03	The Trustees Of The University Of Pennsylvania	Adenovirus de simio de la subfamilia B SADV-28, -27, -29, -32, -33 y -35 y usos de los mismos
JP5661476B2 (ja)	2008-03-04	2015-01-28	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
CN105709221B (zh)	2011-04-06	2020-11-17	拜欧瓦克西姆有限公司	用于预防和/或治疗人中的hiv疾病的药物组合物
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl)	2012-03-12	2016-10-31		Partie rekombinowanych adenowirusów o zmienionych końcach
EP2850194A4 (en)	2012-05-18	2016-06-08	Univ Pennsylvania	APE-ADENOVIRES A1302, A1320, A1331 AND A1337 OF THE FAMILY E AND USES THEREOF
US9624510B2 (en)	2013-03-01	2017-04-18	The Wistar Institute	Adenoviral vectors comprising partial deletions of E3
CN111499733A (zh) *	2013-03-14	2020-08-07	美国安进公司	三型金属蛋白酶（timp-3）组织抑制剂的变体、组合物和方法
ES2836432T3 (es)	2015-03-18	2021-06-25	Janssen Vaccines & Prevention Bv	Ensayos para sistemas de expresión recombinante
CA2981841A1 (en)	2015-04-14	2016-10-20	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
MX2017016105A (es) *	2015-06-12	2018-05-15	Glaxosmithkline Biologicals Sa	Polinucleotidos y polipeptidos de adenovirus.
WO2017011336A1 (en)	2015-07-10	2017-01-19	E.&J. Gallo Winery	System and method for dispensing a beverage
RU2758238C2 (ru)	2016-05-12	2021-10-26	Янссен Вэксинс Энд Превеншн Б.В.	Эффективный и сбалансированный двунаправленный промотор
CN109312362B (zh)	2016-06-20	2022-06-28	扬森疫苗与预防公司	有效和平衡的双向启动子
WO2018026547A1 (en)	2016-08-01	2018-02-08	The Wistar Institute Of Anatomy And Biology	Compositions and methods of replication deficient adenoviral vectors for vaccine applications
KR102111244B1 (ko)	2017-02-09	2020-05-15	얀센 백신스 앤드 프리벤션 비.브이.	이종 유전자의 발현을 위한 강력한 짧은 프로모터

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998010087A1 (en) *	1996-09-06	1998-03-12	Trustees Of The University Of Pennsylvania	Chimpanzee adenovirus vectors
US6733993B2 (en) *	2000-09-15	2004-05-11	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
WO2002022080A2 (en) *	2000-09-15	2002-03-21	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
KR20040043129A (ko) *	2001-06-22	2004-05-22	더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지	세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
MXPA04002631A (es) *	2001-09-20	2004-07-08	Glaxo Group Ltd	Vacunas de adn optimizadas por codon gag-vih.
GB0225788D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
GB0225786D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
CA2539864A1 (en) *	2003-09-24	2005-04-07	Oxxon Therapeutics Limited	Hiv pharmaccines
GB2406336A (en) *	2003-09-24	2005-03-30	Oxxon Pharmaccines Ltd	HIV Pharmaccines
GB0417494D0 (en) *	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine

2006
- 2006-05-10 KR KR1020077029093A patent/KR101451620B1/ko not_active Expired - Fee Related
- 2006-05-10 TW TW095116578A patent/TW200716750A/zh unknown
- 2006-05-10 MX MX2007014038A patent/MX2007014038A/es active IP Right Grant
- 2006-05-10 AU AU2006245920A patent/AU2006245920A1/en not_active Abandoned
- 2006-05-10 SG SG2012041687A patent/SG182173A1/en unknown
- 2006-05-10 CN CN2013100023418A patent/CN103088060A/zh active Pending
- 2006-05-10 JP JP2008510517A patent/JP5175178B2/ja not_active Expired - Fee Related
- 2006-05-10 WO PCT/EP2006/004854 patent/WO2006120034A1/en not_active Ceased
- 2006-05-10 CN CNA2006800162796A patent/CN101384722A/zh active Pending
- 2006-05-10 US US11/913,952 patent/US20090208515A1/en not_active Abandoned
- 2006-05-10 CA CA002608316A patent/CA2608316A1/en not_active Abandoned
- 2006-05-10 ES ES06743016.5T patent/ES2546330T3/es active Active
- 2006-05-10 EP EP06743016.5A patent/EP1880012B1/en active Active
- 2006-05-10 EA EA200702190A patent/EA200702190A1/ru unknown
- 2006-05-10 BR BRPI0608798-1A patent/BRPI0608798A2/pt not_active IP Right Cessation
- 2006-05-10 PE PE2006000493A patent/PE20061372A1/es not_active Application Discontinuation
- 2006-05-10 AR ARP060101875A patent/AR053275A1/es unknown
2007
- 2007-10-22 IL IL186828A patent/IL186828A/en not_active IP Right Cessation
- 2007-11-05 ZA ZA2007/09518A patent/ZA200709518B/en unknown
- 2007-11-06 NO NO20075648A patent/NO20075648L/no not_active Application Discontinuation
- 2007-11-20 MA MA30386A patent/MA29458B1/fr unknown
2012
- 2012-08-24 JP JP2012185395A patent/JP2013046613A/ja active Pending

Also Published As

Publication number	Publication date
MX2007014038A (es)	2008-02-11
EP1880012B1 (en)	2015-07-08
KR101451620B1 (ko)	2014-10-21
SG182173A1 (en)	2012-07-30
IL186828A0 (en)	2008-02-09
ES2546330T3 (es)	2015-09-22
KR20080021659A (ko)	2008-03-07
MA29458B1 (fr)	2008-05-02
AR053275A1 (es)	2007-04-25
JP2008539746A (ja)	2008-11-20
BRPI0608798A2 (pt)	2011-03-15
WO2006120034A8 (en)	2007-11-15
JP5175178B2 (ja)	2013-04-03
IL186828A (en)	2015-06-30
US20090208515A1 (en)	2009-08-20
AU2006245920A1 (en)	2006-11-16
CA2608316A1 (en)	2006-11-16
EP1880012A1 (en)	2008-01-23
CN103088060A (zh)	2013-05-08
ZA200709518B (en)	2014-01-29
CN101384722A (zh)	2009-03-11
EA200702190A1 (ru)	2008-04-28
WO2006120034A1 (en)	2006-11-16
NO20075648L (no)	2008-02-07
JP2013046613A (ja)	2013-03-07
PE20061372A1 (es)	2007-01-16

Publication	Publication Date	Title
TW200716750A (en)	2007-05-01	Vaccine composition
NO20090194L (no)	2009-03-10	Rekombinant viral vaksine
PH12017501583B1 (en)	2023-01-20	Novel proteins specific for cd137
MX358725B (es)	2018-09-03	Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
NZ708144A (en)	2020-03-27	Recombinant adenoviruses and use thereof
WO2021064137A3 (en)	2021-05-14	Multi-specific binding proteins for cancer treatment
WO2009022236A3 (en)	2009-10-01	Immunogen platform
JP2014534202A5 (zh)	2015-12-03
EA201591888A1 (ru)	2016-05-31	Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MD4548B1 (ro)	2018-01-31	Polipeptide care se leagă de CX3CR1
BR112016020688A2 (pt)	2017-10-03	Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2016501015A5 (ja)	2017-07-27	デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
RU2019144161A (ru)	2021-08-05	Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
NZ616304A (en)	2016-01-29	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX352974B (es)	2017-12-15	Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
WO2008054540A3 (en)	2008-09-12	Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
TW200716671A (en)	2007-05-01	Improved nanobodies against tumor necrosis factor-alpha
NZ628385A (en)	2016-09-30	Batches of recombinant adenovirus with altered terminal ends
EP2574170A4 (en)	2013-11-20	IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
NZ608143A (en)	2015-02-27	Recombinant modified vaccinia virus ankara (mva) influenza vaccine
MX2021005345A (es)	2021-09-10	Composiciones y metodos.
WO2017214596A8 (en)	2018-10-04	Compositions and methods for preventing and treating zika virus infection
EP2552490A4 (en)	2013-12-18	INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
WO2008115314A3 (en)	2009-10-15	Flavivirus vaccine vector against influenza virus
SG169325A1 (en)	2011-03-30	Promoters for expression in modified vaccinia virus ankara